Baylor Researchers Uncover Developmental Origins and Treatment Resistance Mechanisms of Rare Pediatric Liver Tumors

Baylor researchers identify WNT signaling as the cause of treatment resistance in rare pediatric HBC liver tumors, mapping a new path for targeted therapies.

By: AXL Media

Published: Mar 17, 2026, 4:37 AM EDT

Source: Information for this report was sourced from Baylor College of Medicine

Decoding the Hybrid Complexity of Pediatric Liver Malignancies

Liver cancer in children, while rare, presents a significant clinical challenge when tumors exhibit characteristics of both hepatoblastoma and hepatocellular carcinoma. A research team at Baylor College of Medicine and Texas Children's Hospital has provided new clarity on these hybrid growths, officially categorized as hepatoblastoma with carcinoma features, or HBC. By applying advanced genetic profiling to 42 patient samples, the investigators mapped the cellular composition of these tumors to understand why they defy conventional treatment. According to Dr. Pavel Sumazin, a professor of pediatrics at Baylor, this third category of liver tumor represents a unique biological entity that requires a distinct therapeutic approach compared to more common pediatric cancers.

Identifying the Molecular Continuum of Cancer Cell Types

Through the use of single-cell DNA and RNA sequencing, the study revealed that HBC tumors are not uniform but consist of a diverse mixture of cancer cells. The researchers identified three distinct populations: cells resembling traditional hepatoblastoma, those mirroring adult-style hepatocellular carcinoma, and a unique HBC-specific cell type that carries molecular markers of both. This discovery highlights a molecular continuum where cells transition between different states. According to the study, HBCs originate from hepatic stem cells that have failed to mature, retaining the resilient and undifferentiated characteristics of early embryonic tissue, which makes them inherently more difficult to eradicate with existing medical protocols.

The Impact of Differentiation Arrest on Patient Survival

The clinical implications of these findings are reflected in the stark differences in survival rates between various pediatric liver cancer types. Data from 41 patients showed that the five year survival rate for typical hepatoblastoma is approximately 80 percent, while the survival rate for those with the HBC subtype drops significantly to around 40 percent. Dr. Sumazin noted that while patients who receive liver transplants tend to have better outcomes, the overall resistance of HBC tumors to chemotherapy and immunotherapy remains a primary concern. The study suggests that the "differentiation arrest" observed in these cells allows the tumor to maintain a stem-like state, effe...